Monoclonal Antibodies - From Concept to Approval

20/21 May 2025, Vienna, Austria

Course No. 22013

header-image

Speakers

Markus Roucka

Markus Roucka

VelaLabs

Dr. Andreas Nechansky

Dr. Andreas Nechansky

VelaLabs

Markus Haberger

Markus Haberger

Roche Diagnostics

Dr. Andrea Hawe

Dr. Andrea Hawe

Coriolis Pharma Research

Dr. Ghazaleh Gouya

Dr. Ghazaleh Gouya

Gouya Insights

Zulfaquar Ahmad Arfi

Zulfaquar Ahmad Arfi

LenioBio

Stefan Iarussa

Stefan Iarussa

ProBioGen

Objectives

At the end of this course, participants will have a comprehensive understanding of monoclonal antibodies (mAbs). From the early development process, through upstream and downstream manufacturing, to different analytical approaches, clinical trials and stability studies. The course is designed to ensure that participants not only understand the theoretical underpinnings of mAb development, but also the practical and regulatory challenges that must be overcome to bring a therapeutic antibody from the laboratory to the clinic and ultimately to the market.

Background

Monoclonal antibodies (mAbs) are increasingly becoming a cornerstone of therapeutic strategies in a wide range of diseases, including oncology, rheumatology and infectious diseases. Their ability to target specific antigens with high precision makes them critical tools in the fight against complex diseases. The global market for monoclonal antibodies is expanding not only because of their efficacy but also because of technological advances in genetic engineering and bioprocessing.

The development of monoclonal antibodies involves a sophisticated and multidisciplinary approach that integrates the fields of molecular biology, genetic engineering, immunology and pharmacology. The complexity of the development process is compounded by the stringent requirements imposed by regulatory authorities to ensure the safety, efficacy and quality of these biopharmaceuticals before they reach the market.

Guidelines from regulatory agencies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) provide structured pathways and requirements for the development and approval of monoclonal antibodies. These guidelines include detailed criteria for the manufacturing process, preclinical and clinical testing and submission of regulatory dossiers.

Given the rigorous and detailed nature of these guidelines, professionals involved in mAb development must have a deep understanding of both the scientific and regulatory landscape. It is essential that these professionals are familiar with critical guidelines such as ICH Q6B, which details test procedures and acceptance criteria for biotechnology and biological products, or ICH Q8(R2), which provides guidance on pharmaceutical development.

Target Group

The programme is aimed at those working in research, clinical trials and anyone interested in developing monoclonal antibodies. By targeting this wide range of professionals, the training aims to create a knowledgeable and skilled workforce capable of advancing the field of monoclonal antibodies from the research phase through to clinical use and successful market entry.

Date / Venue / Presentations / Certificate

Date
Tuesday, 20 May 2025, 09.00 h – 16.30 h
(Registration and Coffee 08.30 h – 09.00 h)
Wednesday, 21 May 2025, 09.00 h – 15.30 h

Venue
Doubletree by Hilton Vienna Schönbrunn
Schlossallee 8
1140 Vienna, Austria
Phone  +43/1/89110
Email info@doubletree-schonbrunn.at

The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site.

After the event, you will automatically receive your certificate of participation.

Programme

Monoclonal Antibodies - From Concept to Approval

Seminar Programme as PDF

World of mAbs: Introduction and Overview – From Idea to Product
  • What are monoclonal antibodies (mAbs)?
  • Conception to market – developing effective mAbs
  • Areas of application: therapeutic applications, diagnostics, research
Analytical Concept for Fc and Fab
  • Antibody structures: Fc and Fab analysis
  • Ligand Binding Assay (LBA) and other techniques
  • Bioassay validation
Production Processes of mAbs: From Upstream to Downstream
  • Regulatory aspects
  • Techniques and technologies
  • Challenges and solutions in scale-up
  • Case studies
Production processes of mAbs: Choosing the right Expression System
  • Exploring platforms for mAbs production
  • Weighing the pros and cons: strategies for monoclonal antibody production
  • Optimizing outcomes: evaluating hosts for efficiency and quality
Purification Methods: Antigen Affinity Purification (Downstream)
  • Principles of antigen-affinity purification: selectivity and specificity
  • Technological advances in affinity media and ligand design
  • Integration into downstream processing: purity, yield and scalability
  • Optimization of purification processes for mAbs
Liquid Chromatography Mass Spectrometry (LCMS)
  • LC-MS in mAbs characterization: sensitivity, specificity and throughput
  • Comparative analysis: when to use LBA vs. LC-MS
  • Glycosylation and its effect
Lyophilization of Monoclonal Antibodies
  •  Basic information on lyophilization – why answd how?
  •  Challenges and opportunities of lyophilization of mAbs
  •  Development of lyophilized formulations and required analytical methods
  •  Lyophilization process development, including QbD and lyomodelling
Clinical Development Plan
  • Blueprint for success: mapping the clinical trial journey
  • Critical strategies for effective clinical development
  • Navigating clinical development stages – Phase I - III
Formulation strategies and stability testing for mAbs
  • Developability assessment and early formulation screenings
  • Phase appropriate formulation strategies for mAbs
  • Conducting stability studies: protocols, parameters and analytical methods
ADC (Antibody Drug Conjugates) - Design and Application
  • The anatomy of ADCs: linkers, drugs and antibodies
  • Clinical applications of ADCs: successes and lessons learned
  • Future directions: innovations in linker chemistry and targeted delivery
Bi- and tri-specific Conjugates - Potential and Challenges
  • Designing bi- and tri-specific antibodies: concepts and constructs
  • Therapeutic potential: targeting complex diseases with multifunctional antibodies
  • Overcoming development challenges: manufacturing, stability and efficacy
Interactive Workshop about the Key Components in the Development of ADCs
This workshop provides a comprehensive introduction to the critical parameters that influence the efficacy and safety of ADCs.
Participants will learn more about the following subjects:
  • How to choose the right target antigen to maximise selectivity?
  • Which properties of the antibody are crucial for optimal binding and stability?
In this workshop participants have also the opportunity to learn and discuss topics such as the selection of the right linker, payload and conjugation method and much more.

stop

This course is part of the GMP Certification Programme "ECA Certified Biotech Manager" Learn more

ECA-Member*: € 1890,-
Non ECA Member*: € 2090,-
EU/GMP Inspectorates*: € 1045,-
APIC Member Discount*: € 1990,-

(All prices excl. VAT). Important notes on sales tax.

* also payable by credit card
American Express Visa Mastercard

icon
Further dates on-site
Further dates on-site
Not available
icon
Further dates online
Further dates online
Not available
icon
Recording
Not available

Do you have any questions?

Please contact us:
Tel.: +49 6221 8444-0
E-Mail: info@gmp-compliance.org

Woman with headset

Go back

Testimonials about our courses and conferences

"Great material and speakers" and "Great speakers a lot of experience and sharing"

Felipe Gonzalez, Mucos Emulsionsgesellschaft mbH
Live Online Training - Granulation & Tableting, September 2024

"The lectures were very informative, interesting and entertaining."

Albert Godoy Hernández, Company synaffix
Live Online Training - GMP Auditor Practice, October 2024

"Really useful training which I will use in my daily work."

Regina Mommaerts, Galapagos NV
Live Online Training - GMP Auditor Practice, October 2024

"Wonderful format of the sessions: Good range of participations and experience in the team. Would love to attend another one soon."

Roopasi Mathi, Wacker Biotech B.V.
Live Online Training - GMP Auditor Practice, October 2024

"Very good balance between general and detailed information"

Dr Ralf Albrecht, Tillotts Pharma AG
Live Online Training - Granulation & Tableting
September 2024

"Nice presentations: easy understanding, quite visual"

Susana Manrique, Boehringer Ingelheim España, S.A,
Live Online Training - Granulation & Tableting, September 2024

“Fantastic course – I really enjoyed the interactive structure & greatly appreciate social activity.”

Anthony Cummins, Sebela Pharmaceuticals, Ireland
GMP Auditor Practice, September 2023

 

“Very well organized, information on point without being overwhelming.”

Eleni Kallinikou, Pharmathen
Live Online Trainng - Pharmaceutical Contracts - Febuary 2024

 

“Good overview of different types of agreements, good to see both the GMP and the legal angle”

Ann Michiels, Johnson&Johnson
Live Online Trainng - Pharmaceutical Contracts, Febuary 2024

 

 

“Well prepared presentations and good presenters. I also like the way of asking questions.”

Alexandra Weidler, Hookipa Biotech GmbH, Austria
Live Online Training – QP Education Course Module A, November 2023